Vaginitis Therapeutics Market Report 2026

The vaginitis therapeutics market size has grown rapidly in recent years. It will grow from $4.43 billion in 2025 to $4.87 billion in 2026 at a compound annual growth rate (CAGR) of 10%. The growth in the historic period can be attributed to increasing prevalence of bacterial vaginosis, limited awareness about vaginal health, reliance on traditional antifungal and antibiotic treatments, growing female population in reproductive age, rising hospital visits for gynecological issues.

The vaginitis therapeutics market size is expected to see rapid growth in the next few years. It will grow to $7.4 billion in 2030 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to development of precision medicine and targeted therapies, expansion of telehealth services, increased patient awareness and education, growth of OTC and home-based treatments, integration of digital monitoring tools in gynecological care. Major trends in the forecast period include personalized vaginitis treatment approaches, rising adoption of non-antibiotic therapeutics, telemedicine for gynecological consultations, growth in over-the-counter vaginitis remedies, focus on reducing recurrence of vaginal infections.

The rising prevalence of sexually transmitted diseases (STDs) is expected to drive the growth of the vaginitis therapeutics market in the coming years. STDs are infections transmitted through sexual contact, often leading to vaginitis, which causes vaginal inflammation and discomfort. Vaginitis therapeutics help alleviate these symptoms, resulting in higher usage of treatment options among women. For example, in July 2024, the UK Health Security Agency reported 401,800 new STI diagnoses in 2023, a 4.7% increase from 383,789 cases in 2022. Consequently, the increasing incidence of STDs is fueling the expansion of the vaginitis therapeutics market.

Key companies in the vaginitis therapeutics sector are focusing on technological innovations, such as science-backed vaginal symptom relief products, to meet the demand for safer, non-systemic treatments that restore vaginal health and address issues like dryness, odor, and irritation. These products use targeted formulations to support the natural vaginal microbiome and maintain pH balance, offering a microbiome-friendly alternative to systemic antibiotics or traditional creams. For instance, in November 2024, Evvy, a US-based women’s health company, launched a prescription vaginal healthcare product line, including boric acid suppositories, hyaluronic acid suppositories, anti-itch vulva cream, and soothing vulva cream, developed with guidance from OBGYNs and microbiome experts. The products restore healthy vaginal pH, alleviate irritation, and support a balanced microbiome, providing therapeutic and preventive benefits while minimizing antimicrobial resistance and disruption to the natural vaginal ecosystem.

In March 2023, GSK, a UK-based pharmaceutical and biotechnology company, collaborated with SCYNEXIS, a US-based biotechnology firm specializing in antifungal therapies, to develop and commercialize innovative treatments for fungal infections. The partnership combines GSK’s global reach with SCYNEXIS’s expertise in antifungal therapies to improve patient outcomes in serious fungal disease management.

Major companies operating in the vaginitis therapeutics market are Pfizer Inc., Merck & Co Inc., Bayer AG, Lupin Pharmaceuticals Inc., Symbiomix Therapeutics Inc., Mission Pharmacal Company, Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals Inc., GlaxoSmithKline plc, Sanofi SA, TherapeuticsMD Inc., Scynexis Inc., Sebela Pharmaceuticals Inc., Daré Bioscience Inc., Mylan N.V., Cidara Therapeutics Inc., Imprimis Pharmaceuticals Inc., Innovus Pharmaceuticals Inc., Evofem Biosciences Inc., Mycovia Pharmaceuticals, Perrigo Company plc, Mithra Pharmaceuticals, Ferring Pharmaceuticals Inc.

North America was the largest region in the global vaginitis therapeutics market in 2025. The regions covered in the vaginitis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vaginitis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the vaginitis therapeutics market by increasing the cost of imported active pharmaceutical ingredients and finished drugs, leading to higher production and treatment costs. This has particularly affected oral and vaginal drug segments and regions reliant on imports such as North America and Europe. While tariffs create price pressures, they also encourage local manufacturing and sourcing strategies, which can strengthen domestic production capabilities and foster innovation in treatment delivery.

The vaginitis therapeutics market research report is one of a series of new reports that provides vaginitis therapeutics market statistics, including vaginitis therapeutics industry global market size, regional shares, competitors with a vaginitis therapeutics market share, detailed vaginitis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the vaginitis therapeutics industry. This vaginitis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vaginitis therapeutics refer to the use of drugs, including antifungal agents, antibiotics, and hormonal medications, for treating vaginal infections. These medications help relieve symptoms such as itching, discharge, and pain.

The main drug types in vaginitis therapeutics include nitroimidazole compounds, lincosamide antibiotics, triazoles, and imidazoles. Nitroimidazoles are antimicrobial agents that act against parasites, mycobacteria, and anaerobic gram-positive and gram-negative bacteria. Administration routes include oral, topical, and vaginal, and the treatments are indicated for bacterial vaginosis, trichomoniasis, vulvovaginal candidiasis, and other vaginal infections. End users include hospitals, ambulatory surgical centers, specialized gynecology centers, and clinics.

The vaginitis therapeutics market includes revenues earned by entities by nonhormonal therapy, and antioxidant therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.